(NASDAQ: EPRX) Eupraxia Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Eupraxia Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast EPRX's revenue for 2027 to be $178,208,015, with the lowest EPRX revenue forecast at $178,208,015, and the highest EPRX revenue forecast at $178,208,015. On average, 1 Wall Street analysts forecast EPRX's revenue for 2028 to be $1,247,456,105, with the lowest EPRX revenue forecast at $1,247,456,105, and the highest EPRX revenue forecast at $1,247,456,105.
In 2029, EPRX is forecast to generate $3,207,744,270 in revenue, with the lowest revenue forecast at $3,207,744,270 and the highest revenue forecast at $3,207,744,270.